Corbus Pharmaceuticals Holdings, Inc. (CRBP) |
|
9.8101 0.12 (1.24%)
|
06-06 15:03 |
|
Open: |
9.64 |
Pre. Close: |
9.69 |
|
High:
|
9.96 |
Low:
|
9.49 |
|
Volume:
|
11,258 |
Market Cap:
|
41(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 2:47:44 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 13.39 One year: 15.64 |
| Support: |
Support1: 9.22 Support2: 7.82 |
| Resistance: |
Resistance1: 11.47 Resistance2: 13.39 |
| Pivot: |
10.15 |
| Moving Average: |
MA(5): 9.72 MA(20): 10.01
MA(100): 6.61 MA(250): 6.05 |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.3 |
| Stochastic oscillator: |
%K(14,3): 36.4 %D(3): 35.4 |
| RSI: |
RSI(14): 51.4 |
| 52-week: |
High: 13.17 Low: 2.1 |
| Average Vol(K): |
3-Month: 459 (K) 10-Days: 30 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CRBP ] has closed above bottom band by 35.4%. Bollinger Bands are 26.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
10 - 10.05 |
10.05 - 10.09 |
|
Low:
|
9.45 - 9.51 |
9.51 - 9.55 |
|
Close:
|
9.61 - 9.69 |
9.69 - 9.76 |
|
Company Description |
|
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts. |
Headline News |
Mon, 05 Jun 2023
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Wed, 31 May 2023
Corbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference - Yahoo Finance
Thu, 25 May 2023
Corbus Pharmaceuticals Holdings Inc. stock falls Thursday, underperforms market - MarketWatch
Tue, 16 May 2023
Is Corbus Pharmaceuticals Holdings Inc (CRBP) a Good Buy in the Biotechnology Industry? - InvestorsObserver
Fri, 12 May 2023
Is Corbus Pharmaceuticals Holdings Inc (CRBP) a Stock to Watch After Losing -9.04% This Week? - InvestorsObserver
Thu, 11 May 2023
Oppenheimer Upgrades Corbus Pharmaceuticals Holdings (CRBP) - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
4 (M) |
| Shares Float |
4 (M) |
|
% Held by Insiders
|
0.3 (%) |
|
% Held by Institutions
|
9.3 (%) |
|
Shares Short
|
141 (K) |
|
Shares Short P.Month
|
297 (K) |
Stock Financials |
|
EPS
|
-13.4 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.9 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-37.1 |
|
Return on Equity (ttm)
|
-130.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-3.83 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-10.16 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-42 (M) |
|
Levered Free Cash Flow
|
-22 (M) |
Stock Valuations |
|
PE Ratio
|
-0.74 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.51 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.99 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
